{"id":957680,"date":"2026-05-04T16:03:17","date_gmt":"2026-05-04T20:03:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/"},"modified":"2026-05-04T16:03:17","modified_gmt":"2026-05-04T20:03:17","slug":"cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/","title":{"rendered":"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time<\/em>\n      <\/p>\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., May  04, 2026  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will report topline results from ACACIA-HCM (<strong>A<\/strong>ssessment <strong>C<\/strong>omparing <strong><em>A<\/em><\/strong><em>ficamten<\/em> to Placebo on <strong>C<\/strong>ardiac Endpoints <strong>I<\/strong>n <strong>A<\/strong>dults with <strong>N<\/strong>on-Obstructive <strong>HCM<\/strong>) on Tuesday, May 5, 2026. Following the announcement, Cytokinetics will host a conference call at 8:00 AM Eastern Time to discuss the results.<\/p>\n<p align=\"justify\">The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EOdZIA7bKrd_JfzDUH8zklyhjg8mvkBWdvkM5uDrxfqgk10054ZLTtritZpK15HbEGRXLiumBz-JQ3Iyaf188sdLN8Nr_8vEgRgFoWuBoa8a8QQD7avzoh8ohFB5FgH6L4ywkbBleSaeyxbRwJTkVg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.cytokinetics.com<\/a> or the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_UW79TfOzAuWYGvfO4cA6oXcJcGHJOHq6jDPv1BEhllt-z6Vcou5XLUJjnDSe53i8X-8RKINnzccziVCQ-oxUG2vUqLcUADwdmN9ASuMzK1v_mqSxDunxYgzZIfcLVPH\" rel=\"nofollow\" target=\"_blank\">ACACIA-HCM Topline Results<\/a>. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months.<\/p>\n<p align=\"justify\">\n        <strong>About Cytokinetics <\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics\u2019 MYQORZO<sup>\u00ae<\/sup> (<em>aficamten<\/em>) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing <em>omecamtiv mecarbil<\/em>, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and <em>ulacamten<\/em>, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.<\/p>\n<p align=\"justify\">For additional information about Cytokinetics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6FFwqcxjwof9LELALZjqEkwpdjI4lF_gsRxJRaiuS_HGf7kCLxwOjMDxHAm0hWR3LYowW1lyJbk7ei_QFJygXKnP9JLyp0aYpRknpZIs6rg=\" rel=\"nofollow\" target=\"_blank\">www.cytokinetics.com<\/a>\u00a0and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j2hin1bWY3fP4lIORW54qNlM1SZ-3P5kcd117zlaMjjh5U0MWzlOINg6LiPb6Ch4aDssBJXxDNFhDgVa_6ZkR4yYOWzQ0FDTRXHp6y9qehuGy9Fr2_V37o3JI875M3Dye2h9TmTjml4vnukNiT21Pxplw1hAvEhSZWEYljVpfOLBj_UTK1_Pyza_2C2rwrnptBOrt4Q9J-PLY4BJFhT__A==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wqtEUQkS5Mv5sfKc-ogoOCxwPt49Ve-h94Q_yJ3La2a2vxYB04nrJkoQQ1cA6NKsiB7xIpNHMpGN5hXPZF9t-Po-mxmxhKQwUDRvv9d-7pbwlgPNeUHqv5P90vaE-y5FDKkcH3rkHQezIR3ICP3YltnXV906K8DgeTgoKs2PTYOioXpqvP23CeHwfnL8kFssZsl5yqhOoBtDg6e76rzC39UliuarL7sCAyrLfFcuMa1GgRbbES2jKrlp6TvHo59YygMvDKJkZDakVhOgWA0sqw==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cb4VLBg1m2Uukttd2UwPTPB58E-xYE_RBmdaiaZx9YHt7mIIAqg1SANyGpQJsG5sMmi1IUHOtCLxFPszXL-3IbFlvknFc9ck8aUdYjUHMuGDu2Kabow2RKsgThN9UpILXsYeYzM0H9KZXDuyqnZ-uMT7Pub9Ig0LnElcuGILKd_YfEzVJWl6bQ9GeRuz4EMTbStoV4L0DgJhKqnyfP8feqaLvDRiGRn0cjbTlS4lZjhRvm1191z-4xmyb_tsvReL\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=89vPzgkAp4rnxua0b-oysI__VaFh2DfMp75ELcLBIT8sqC-TftLihNKGTr6Dm_fjJpMuc5LL9o_rft2RlnkN1m_JExtMSAv2s7oplwHAaHgLjYcF19xS0pxHMb5qN23yJe4K7Bfls7KkFC3b2mrrntufU6t4FG_BnqMC3BX7bnlN1h1ZwjvV8eNpFCZS2UrCavP7DGYpf1ROpFqyvJmUWPjAN2R1dVkfYn-OSBYoWcVpBCYcI2zlXrcxC05GCaj5sUshTsdJVJlIQw5TmILkqQ==\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Disclaimer<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Omecamtiv mecarbil <\/em>and<em> ulacamten\u00a0<\/em>are investigational medicines. They\u00a0have not been approved\u00a0nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\u2019s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics\u2019 and its partners\u2019 research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics\u2019 business outlines in Cytokinetics\u2019 filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics\u2019 actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">CYTOKINETICS\u00ae and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.<\/p>\n<p align=\"justify\">MYQORZO<sup>\u00ae<\/sup> is a registered trademark of Cytokinetics in the U.S. and the European Union.<\/p>\n<p align=\"justify\">Contact:<br \/>Cytokinetics <br \/>Diane Weiser<br \/>Senior Vice President, Corporate Affairs<br \/>(415) 290-7757<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTBiYjE4NDEtNzIxMy00YTVlLWIzZmMtN2E1ZDcyMjJiOTY5LTEwMTY2NzYtMjAyNi0wNS0wNC1lbg==\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will report topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) on Tuesday, May 5, 2026. Following the announcement, Cytokinetics will host a conference call at 8:00 AM Eastern Time to discuss the results. The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at https:\/\/ir.cytokinetics.com or the following link: ACACIA-HCM Topline Results. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months. About Cytokinetics &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957680","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will report topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) on Tuesday, May 5, 2026. Following the announcement, Cytokinetics will host a conference call at 8:00 AM Eastern Time to discuss the results. The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at https:\/\/ir.cytokinetics.com or the following link: ACACIA-HCM Topline Results. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months. About Cytokinetics &hellip; Continue reading &quot;Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T20:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026\",\"datePublished\":\"2026-05-04T20:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/\"},\"wordCount\":547,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/\",\"name\":\"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=\",\"datePublished\":\"2026-05-04T20:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 - Market Newsdesk","og_description":"Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will report topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) on Tuesday, May 5, 2026. Following the announcement, Cytokinetics will host a conference call at 8:00 AM Eastern Time to discuss the results. The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at https:\/\/ir.cytokinetics.com or the following link: ACACIA-HCM Topline Results. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months. About Cytokinetics &hellip; Continue reading \"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-04T20:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026","datePublished":"2026-05-04T20:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/"},"wordCount":547,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/","name":"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=","datePublished":"2026-05-04T20:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU3NSM3NTgxODUzIzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy-on-may-5-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957680"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957680\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}